Lactose (India) Limited (524202) Fair Value & Analysis

Healthcare · IN · Market cap ₹178M

Below-average quality, screening 31% undervalued on our models.

What matters now

• The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain.
• Our model range runs from ₹98.11 (bear) to ₹163.63 (bull), base ₹130.91. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 38/100 (below-average quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹23.60 – ₹235.75 · fair‑value band ₹98.11 – ₹163.63 · the ₹99.65 price screens below the ₹130.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Lactose (India) Limited (524202) currently trades at ₹99.65, while our model-based Fair Value estimate is ₹130.91, implying the stock looks roughly 31.4% undervalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Lactose (India) Limited generated revenue of ₹346M at a net margin of -6.7%. Revenue declined 19.4% year over year. It earns a return on equity of -7.0%. Net debt stands at ₹611M. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹98.11 (bear case) to ₹163.63 (bull case); at ₹99.65, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 31% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 31%, 524202 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹203.05) versus DCF Models (₹6.44). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Lactose (India) Limited manufactures and trades in pharmaceutical products in India. The company offers lactose monohydrate; dry granulated, film, and lacquer coated tablets; and pharmaceutical products in liquid dose forms.

Full company description

Lactose (India) Limited manufactures and trades in pharmaceutical products in India. The company offers lactose monohydrate; dry granulated, film, and lacquer coated tablets; and pharmaceutical products in liquid dose forms. It also provides disaccharide lactulose, an active pharmaceutical ingredient that is used in the treatment of constipation, hepatitis encephalopathy, intestinal microflora, dental care, diabetes, and chronic liver disease, as well as for use as a prebiotic; and galacto-oligosaccharides, a prebiotic for use in dairy and bakery products, beverages, infant and clinical nutrition, and geriatric nutrition applications, as well as in products for children or adolescents. The company also exports its products to Russia, Kazakhstan, Belarus, Nigeria, Sri Lanka, and other countries. Lactose (India) Limited was founded in 1991 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Lactose (India) Limited reported revenue of ₹1.6B in FY2026 versus ₹459M in FY2022, a compound +37.3%/yr. Reported net income was ₹60.6M in FY2026, compounding +25.4%/yr from FY2022.

Watch 524202: get an alert when its fair value changes →

Peer Group

Health Care · 2285 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)

Valuation Multiples vs Health Care median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.